A spike in volatility following a lacklustre jobs report in the United States and a rate hike in Japan masked a broadly solid second quarter earnings season.
“I’m a long-term investor, but the long term is the sum of all the short terms so every quarterly earnings report matters,” says portfolio manager Mark Casey. “I’m interested in evidence that my long-term thesis is going as expected, better than expected, or possibly worse than expected.”
With that in mind, here are three investment ideas from the latest round of earnings reports.
Earnings outlook softens for 2024, but remains solid
Executives at large technology companies emphasized during their earnings calls how investments in artificial intelligence have already contributed to business growth. These statements may have been made to address investor concerns about increased capital expenditure to support AI.
“Every AI-driven company seems to have a good story about how AI is showing some positive impact to revenue, which is one reason their stocks aren’t too far off from their all-time highs,” Casey says.
Meta CEO Mark Zuckerberg noted that “advances in AI continue to improve the quality of recommendations and drive engagement.” One of the company’s long-term goals is to provide marketers the ability to automate the processes of creating and testing advertising content.
Still, investors are nervous about increased spending. “In some cases the check sizes are getting so large it’s hard to imagine the investment return can be there,” Casey says.
If a recession hits, lower spending from customers could crimp profits, but the impacts to long-term stock prices are harder to predict.
“My simplifying approach to investing is to think four to eight years out and assume there is a recession between now and then. Then I try to determine which companies are likely to be larger and more profitable at that point in the future than their stock prices currently assume,” Casey says. The exercise helps him work through near-term volatility and avoid rash decisions.
The duopoly for weight loss and diabetes drugs from Eli Lilly and Novo Nordisk is likely to continue for some time, says equity analyst Christopher Lee, who covers U.S. pharmaceuticals and biotechnology companies.
Eli Lilly, which sells Mounjaro and Zepbound, aggressively invested in manufacturing capacity as high demand landed those products on the U.S. Food and Drug Administration’s shortage list. In early August, the government’s database indicated they are now available.
“Competitors are coming around to the idea that they need to have a product that differs from or is complementary to obesity drugs currently on the market,” Lee says. For example, some companies are working on drugs that will preserve muscle mass as people lose weight.
The moat has widened because Eli Lilly and Novo Nordisk, maker of Ozempic and Wegovy, have invested billions into their franchises over the past 20 years. “By the time a competitor has a product, Eli Lilly and Novo Nordisk will have built a strong wall with commercial insurers. Often referred to as a rebate wall, the practice makes it difficult for competitors to gain traction for their drugs,” Lee notes.
Meanwhile, investors concerned about a slowdown in the economy could take the opportunity to review their health care exposure overall, Lee adds. The sector has tended to hold up well compared to the S&P 500 in a downturn as opting out of life-saving medication is usually not a choice for most consumers.
U.S. health care stocks have recently held up
After raising prices considerably in the wake of the pandemic, McDonald’s and other fast-food companies are offering more affordable options to win back unhappy customers, says equity investment analyst Betsy Lind.
“McDonald’s has traditionally done well in an environment where consumers pull back on spending, but it pushed its pricing so much higher over the last few years that it lost traffic among lower income consumers,” Lind says.
Fast-food companies are now launching national value meals and actively competing for customers. “They can’t raise prices, so they need to grow volume.”
Meanwhile, growth continues for restaurant and food delivery companies such as DoorDash, in part because they’ve expanded their services to include grocery deliveries. Inflation for food sold in grocery stores has declined faster than restaurant inflation, Lind notes, adding that the gap is expected to narrow.
Consumers dined at home as restaurant inflation remains high
Lind thinks McDonald’s could regain customers because the company’s speed of service and uncomplicated menu haven’t changed. McDonald’s same store sales in the U.S. declined 0.7% in the second quarter compared to last year. The company’s stock has declined roughly 7.5% this year as of August 15.
In contrast, companies like Sweetgreen, Chipotle and Cava Group that cater to higher income, health-conscious consumers continue to show strong growth. “There is a long-term theme of people shifting to these options, but they’re not the reason fast-food companies are hurting,” Lind says.
Recent market volatility showed how impulsive investors can be as concerns of a looming recession took hold. And just as quickly, equity markets staged a comeback. Overall, quarterly earnings have generally been strong, with some signs that lower income consumers continue to moderate their spending.
Markets will likely continue to have bouts of volatility in the short term as sentiment shifts and markets move on emotions. “In the long term, however, a company’s stock price tends to accurately reflect what the company is economically worth,” Casey concludes.
S&P 500 Health Care comprises those companies included in the S&P 500 that are classified as members of the GICS Health Care sectors.
United States
RELATED INSIGHTS
Global Equities
Market Volatility
Commissions, trailing commissions, management fees and expenses all may be associated with investments in investment funds. Please read the prospectus before investing. Investment funds are not guaranteed or covered by the Canada Deposit Insurance Corporation or by any other government deposit insurer. For investment funds other than money market funds, their values change frequently. For money market funds, there can be no assurances that the fund will be able to maintain its net asset value per security at a constant amount or that the full amount of your investment in the fund will be returned to you. Past performance may not be repeated.
Unless otherwise indicated, the investment professionals featured do not manage Capital Group‘s Canadian investment funds.
References to particular companies or securities, if any, are included for informational or illustrative purposes only and should not be considered as an endorsement by Capital Group. Views expressed regarding a particular company, security, industry or market sector should not be considered an indication of trading intent of any investment funds or current holdings of any investment funds. These views should not be considered as investment advice nor should they be considered a recommendation to buy or sell.
Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This information is intended to highlight issues and not be comprehensive or to provide advice. For informational purposes only; not intended to provide tax, legal or financial advice. We assume no liability for any inaccurate, delayed or incomplete information, nor for any actions taken in reliance thereon. The information contained herein has been supplied without verification by us and may be subject to change. Capital Group funds are available in Canada through registered dealers. For more information, please consult your financial and tax advisors for your individual situation.
Forward-looking statements are not guarantees of future performance, and actual events and results could differ materially from those expressed or implied in any forward-looking statements made herein. We encourage you to consider these and other factors carefully before making any investment decisions and we urge you to avoid placing undue reliance on forward-looking statements.
The S&P 500 Composite Index (“Index”) is a product of S&P Dow Jones Indices LLC and/or its affiliates and has been licensed for use by Capital Group. Copyright © 2024 S&P Dow Jones Indices LLC, a division of S&P Global, and/or its affiliates. All rights reserved. Redistribution or reproduction in whole or in part are prohibited without written permission of S&P Dow Jones Indices LLC.
FTSE source: London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2024. FTSE Russell is a trading name of certain of the LSE Group companies. "FTSE®" is a trade mark of the relevant LSE Group companies and is used by any other LSE Group company under licence. All rights in the FTSE Russell indices or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indices or data and no party may rely on any indices or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication. The index is unmanaged and cannot be invested in directly.
BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively “Bloomberg”). Bloomberg or Bloomberg’s licensors own all proprietary rights in the Bloomberg Indices. Neither Bloomberg nor Bloomberg’s licensors approves or endorses this material, or guarantees the accuracy or completeness of any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith.
MSCI does not approve, review or produce reports published on this site, makes no express or implied warranties or representations and is not liable whatsoever for any data represented. You may not redistribute MSCI data or use it as a basis for other indices or investment products.
Capital believes the software and information from FactSet to be reliable. However, Capital cannot be responsible for inaccuracies, incomplete information or updating of the information furnished by FactSet. The information provided in this report is meant to give you an approximate account of the fund/manager's characteristics for the specified date. This information is not indicative of future Capital investment decisions and is not used as part of our investment decision-making process.
Indices are unmanaged and cannot be invested in directly. Returns represent past performance, are not a guarantee of future performance, and are not indicative of any specific investment.
All Capital Group trademarks are owned by The Capital Group Companies, Inc. or an affiliated company in Canada, the U.S. and other countries. All other company names mentioned are the property of their respective companies.
Capital Group funds are offered in Canada by Capital International Asset Management (Canada), Inc., part of Capital Group, a global investment management firm originating in Los Angeles, California in 1931. Capital Group manages equity assets through three investment groups. These groups make investment and proxy voting decisions independently. Fixed income investment professionals provide fixed income research and investment management across the Capital organization; however, for securities with equity characteristics, they act solely on behalf of one of the three equity investment groups.
The Capital Group funds offered on this website are available only to Canadian residents.